Cargando…

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT

BACKGROUND: Norm-based scores used to assess cognitive ability have clinical value when describing functioning of patients with neuronopathic disorders compared with unaffected, same-age peers. However, they have limitations when used to assess change in cognitive ability between two timepoints, esp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yee, Karen S., Chirila, Costel, Davenport, Eric, Mladsi, Deirdre, Barnett, Christine, Kronenberger, William G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621086/ https://www.ncbi.nlm.nih.gov/pubmed/37915038 http://dx.doi.org/10.1186/s13023-023-02957-2

Ejemplares similares

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
por: Hogan, Melissa J., et al.
Publicado: (2020)

Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration
por: Chung, Jou-Ku, et al.
Publicado: (2016)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Projected Retained Ability Score (PRAS): A New Methodology for Quantifying Absolute Change in Norm-Based Psychological Test Scores Over Time
por: Kronenberger, William G., et al.
Publicado: (2019)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Comparative study of idursulfase beta and idursulfase in vitro and in vivo
por: Kim, Chihwa, et al.
Publicado: (2017)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Pharmacokinetics and Bioavailability of a Therapeutic Enzyme (Idursulfase) in Cynomolgus Monkeys after Intrathecal and Intravenous Administration
por: Xie, Hongsheng, et al.
Publicado: (2015)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
por: Giugliani, Roberto, et al.
Publicado: (2021)

CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
por: Calias, Pericles, et al.
Publicado: (2012)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II
por: Kim, Katherine H., et al.
Publicado: (2014)

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
por: Sonoda, Hiroyuki, et al.
Publicado: (2018)

Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course
por: Seo, Joo-Hyun, et al.
Publicado: (2020)

PRAS40 signaling in tumor
por: Lv, Dan, et al.
Publicado: (2017)

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry
por: Racoma, Marie Julianne C., et al.
Publicado: (2021)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

PRAS40 hyperexpression promotes hepatocarcinogenesis
por: Qi, Zhaolai, et al.
Publicado: (2020)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
por: Koto, Yuta, et al.
Publicado: (2023)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I
por: Dickson, P.I., et al.
Publicado: (2015)

Airway Findings in Patients with Hunter Syndrome Treated with Intravenous Idursulfase
por: De Vuyst, Richard, et al.
Publicado: (2023)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II
por: Yamamoto, Ryuji, et al.
Publicado: (2021)

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Grant, Nathan
Publicado: (2020)

Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
por: de Castro, María José, et al.
Publicado: (2021)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022)

mTOR/PRAS40 interaction: Hypertrophy or proliferation
por: Völkers, Mirko, et al.
Publicado: (2013)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020)

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2019)

Cognitive Abilities of Dogs with Mucopolysaccharidosis I: Learning and Memory
por: Provoost, Lena, et al.
Publicado: (2020)

Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II
por: Ngu, Lock-Hock, et al.
Publicado: (2017)

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fcnghlmm6075gek2jmeg5qr4to